Mercer Capital Advisers’s AstraZeneca AZN Stock Holding History

Mercer Capital Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$22K	–	156
2020 Q3	$22K	Buy	200 +50	+33%	+$5.56K	0.01%	162
2020 Q2	$16K	Hold	150	–	–	0.01%	168
2020 Q1	$13K	Hold	150	–	–	0.01%	169
2019 Q4	$15K	Hold	150	–	–	0.01%	183
2019 Q3	$13K	Hold	150	–	–	0.01%	189
2019 Q2	$12K	Hold	150	–	–	0.01%	191
2019 Q1	$12K	Hold	150	–	–	0.01%	195
2018 Q4	$11K	Hold	150	–	–	0.01%	197
2018 Q3	$12K	Hold	150	–	–	0.01%	203
2018 Q2	$11K	Hold	150	–	–	0.01%	213
2018 Q1	$10K	Hold	150	–	–	0.01%	214
2017 Q4	$10K	Hold	150	–	–	0.01%	209
2017 Q3	$10K	Hold	150	–	–	0.01%	215
2017 Q2	$10K	Hold	150	–	–	0.01%	224
2017 Q1	$9K	Hold	150	–	–	0.01%	237
2016 Q4	$8K	Sell	150 -150	-50%	-$8.52K	0.01%	243
2016 Q3	$20K	Hold	300	–	–	0.02%	208
2016 Q2	$18K	Hold	300	–	–	0.01%	212
2016 Q1	$17K	Hold	300	–	–	0.01%	209
2015 Q4	$20K	Buy	+300	New	+$19.7K	0.02%	213

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mercer Capital Advisers's AZN Position: Q4 2020 in Review

Mercer Capital Advisers sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 200 shares — an estimated $22K sold.

Mercer Capital Advisers first reported a position in AZN in Q4 2015 and held it in 20 quarters. The position peaked at $22K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

Mercer Capital Advisers reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
Mercer Capital Advisers sold 200 AstraZeneca shares in Q4 2020, an estimated $22K.
Mercer Capital Advisers first reported a position in AstraZeneca in Q4 2015 and held it in 20 quarters.
Mercer Capital Advisers's AstraZeneca position peaked at $22K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Mercer Capital Advisers's 13F filing for Q4 2020, filed 28 Jan 2021.